SEPTEMBER 15, 2025
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing
SEPTEMBER 11, 2025
Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for
SEPTEMBER 3, 2025
Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable
SEPTEMBER 1st, 2025
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Biophytis provides a detailed update on its clinical and regulatory plan for
AUGUST 28, 2025
Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis announced that both Part I (European Medicines Agency scientific review)
AUGUST 5, 2025
Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Biophytis announces the establishment of a non-dilutive bond financing line for a maximum amount
JULY 30, 2025
Biophytis Joins Silver Innov’, an Incubator Dedicated to the Silver Economy Biophytis is relocating to Silver Innov, an incubator and business center specialized in innovation,
JULY 16, 2025
Biophytis Wins Major Legal Victory Before the French Court of Cassation Biophytis announces a major legal victory. On July 9, 2025, the French Court of
JULY 15, 2025
Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Biophytis SA, a pioneering force in the development of transformative therapies for
JULY 11, 2025
Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as